+

WO1997026910A3 - Vaccin antitumoral pour le traitement immunitaire des tumeurs malignes - Google Patents

Vaccin antitumoral pour le traitement immunitaire des tumeurs malignes Download PDF

Info

Publication number
WO1997026910A3
WO1997026910A3 PCT/DE1997/000172 DE9700172W WO9726910A3 WO 1997026910 A3 WO1997026910 A3 WO 1997026910A3 DE 9700172 W DE9700172 W DE 9700172W WO 9726910 A3 WO9726910 A3 WO 9726910A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
immunotherapy
malignant tumours
tumour vaccine
thermal shock
Prior art date
Application number
PCT/DE1997/000172
Other languages
German (de)
English (en)
Other versions
WO1997026910A2 (fr
Inventor
Juergen Milleck
Werner Reichardt
Rainer Benndorf
Windfried Liebrich
Peter Schlag
Original Assignee
Max Delbrueck Centrum
Juergen Milleck
Werner Reichardt
Rainer Benndorf
Windfried Liebrich
Peter Schlag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19602985A external-priority patent/DE19602985A1/de
Priority claimed from DE19604380A external-priority patent/DE19604380A1/de
Application filed by Max Delbrueck Centrum, Juergen Milleck, Werner Reichardt, Rainer Benndorf, Windfried Liebrich, Peter Schlag filed Critical Max Delbrueck Centrum
Publication of WO1997026910A2 publication Critical patent/WO1997026910A2/fr
Publication of WO1997026910A3 publication Critical patent/WO1997026910A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un vaccin antitumoral dans lequel l'immunogénicité des cellules tumorales, des antigènes associés aux cellules ou des structures antigéniques partielles est renforcée par modification génétique ou par liaison chimique à une protéine de choc thermique exogène. On utilise de préférence des protéines de choc d'origine microbienne ou leurs gènes, qui sont obtenus à partir de mycobactéries, Escherichia coli ou Chlamydia trachomatis.
PCT/DE1997/000172 1996-01-27 1997-01-27 Vaccin antitumoral pour le traitement immunitaire des tumeurs malignes WO1997026910A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19602985A DE19602985A1 (de) 1996-01-27 1996-01-27 Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
DE19602985.6 1996-01-27
DE19604380A DE19604380A1 (de) 1996-02-07 1996-02-07 Tumorimpfstoff für die Immuntherapie von malignen Tumoren
DE19604380.8 1996-02-07

Publications (2)

Publication Number Publication Date
WO1997026910A2 WO1997026910A2 (fr) 1997-07-31
WO1997026910A3 true WO1997026910A3 (fr) 1997-10-02

Family

ID=26022430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000172 WO1997026910A2 (fr) 1996-01-27 1997-01-27 Vaccin antitumoral pour le traitement immunitaire des tumeurs malignes

Country Status (1)

Country Link
WO (1) WO1997026910A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221488A1 (fr) 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Proteines du stress et leurs utilisations
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6663868B1 (en) 1995-08-18 2003-12-16 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
DK0941315T3 (da) * 1996-11-26 2006-05-15 Stressgen Biotechnologies Corp Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
IL134341A0 (en) 1997-08-05 2001-04-30 Stressgen Biotechnologies Corp Compositions for inducing an immune response containing an hpv protein antigen
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
EP2295065B1 (fr) 1998-02-20 2013-10-09 The University of Miami Complexe de peptide antigènes à protéines de choc thermique modifiées
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
JP2003510334A (ja) 1999-09-30 2003-03-18 コリクサ コーポレイション 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU1814101A (en) * 2000-01-14 2001-07-24 Massachusetts Institute Of Technology In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US20020110566A1 (en) 2000-06-26 2002-08-15 Neefe John R. Human papilloma virus treatment
JP2005505238A (ja) 2001-02-05 2005-02-24 ストレスゲン バイオテクノロジーズ コーポレイション Ｂ型肝炎ウイルスの治療法
WO2003015712A2 (fr) 2001-08-20 2003-02-27 University Of Connecticut Health Center Procedes de preparation de compositions a base de proteines du stress ou de $g(a)-2- macroglobuline utilisees dans le traitement du cancer et des maladies infectieuses
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2017083337A1 (fr) * 2015-11-10 2017-05-18 Ohio State Innovation Foundation Méthodes et compositions associées à une affinité humorale accélérée
CA3040123A1 (fr) 2016-10-11 2018-04-19 University Of Miami Vecteurs et cellules de vaccin pour immunite contre le virus zika
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011513A1 (fr) * 1992-11-13 1994-05-26 Medical Research Council Proteines de choc thermique et traitement de tumeurs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011513A1 (fr) * 1992-11-13 1994-05-26 Medical Research Council Proteines de choc thermique et traitement de tumeurs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CELIO L. SILVA ET AL.: "CHARACTERIZATION OF T CELLS THAT CONFER A HIGH DEGREE OF PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS IN MICE AFTER VACCINATION WITH TUMOR CELLS EXPRESSING MYCOBACTERIAL HSP65", INFECTION AND IMMUNITY, vol. 64, no. 7, July 1996 (1996-07-01), WASHINGTON US, pages 2400 - 2407, XP002037579 *
MICHAEL HEIKE ET AL.: "HEAT SHOCK PROTEIN-PEPTIDE COMPLEXES FOR USE IN VACCINES", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 60, August 1996 (1996-08-01), pages 153 - 158, XP002037580 *
NATHALIE E. BLACHERE ET AL.: "HEAT SHOCK PROTEIN VACCINES AGAINST CANCER", JOURNAL OF IMMUNOTHERAPY, vol. 14, November 1993 (1993-11-01), pages 352 - 356, XP002037576 *
NATHALIE E. BLACHERE ET AL.: "HEAT SHOCK PROTEIN-BASED CANCER VACCINES AND RELATED THOUGHTS ON IMMUNOGENICITY OF HUMAN TUMORS", SEMINARS IN CANCER BIOLOGY, vol. 6, December 1995 (1995-12-01), pages 349 - 355, XP002037577 *
PRAMOD K. SRIVASTAVA ET AL.: "HEAT SHOCK PROTEIN-PEPTIDE COMPLEXES IN CANCER IMMUNOTHERAPY", CURRENT OPINION IN IMMUNOLOGY, vol. 6, 1994, LONDON GB, pages 728 - 732, XP002037578 *
SATISH JINDAL: "HEAT SHOCK PROTEINS:APPLICATIONS IN HEALTH AND DISEASE", TRENDS IN BIOTECHNOLOGY, vol. 14, January 1996 (1996-01-01), CAMBRIDGE GB, pages 17 - 20, XP002037582 *
TAMÁS SCHWEIGHOFFER: "TUMOR CELLS EXPRESSING A RECALL ANTIGEN ARE POWERFUL CANCER VACCINES", EUR. J. IMMUNOL., vol. 26, November 1996 (1996-11-01), pages 2559 - 2564, XP002037581 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same

Also Published As

Publication number Publication date
WO1997026910A2 (fr) 1997-07-31

Similar Documents

Publication Publication Date Title
WO1997026910A3 (fr) Vaccin antitumoral pour le traitement immunitaire des tumeurs malignes
DE69727966D1 (de) Ein mit krebs assoziiertes antigen kodierendes isoliertes nukleinsäuremolekül, das antigen selbst, und dessen verwendungen
AU3431497A (en) DNA immunization against Chlaymdia infection
WO2000066067A3 (fr) Antigenes microbiens associes aux affections intestinales inflammatoires et procedes pour l'utilisation de ces antigenes
EP1335023A3 (fr) Méthodes et réactifs pour induire une vaccination basée sur la production de cellules T CD8+
EP0332424A3 (fr) Anticorps chimériques, dirigés contre l'antigène humaine carcino-embryonique
WO2000029428A3 (fr) Polypeptide
WO2001046420A3 (fr) Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
WO1999029341A3 (fr) PROCEDES PERMETTANT DE RENFORCER DES REPONSES IMMUNITAIRES DE PROTECTION AU MOYEN DE POLYPEPTIDES $i(LEISHMANIA)
WO2003042362A3 (fr) Pgc-1$g(b), un nouvel homologue du pgc-1 et leurs utilisations
HUP9902438A2 (hu) Parapoxvírus vektorok
WO2004093808A3 (fr) Nouveaux antigenes associes a une tumeur
WO2001038357A3 (fr) Nouveau membre de la famille des facteurs de croissance des fibroblastes, appele jaffa, et utilisations correspondantes
WO2000075358A3 (fr) Molecules toll et leurs utilisations
WO2001073028A3 (fr) Nouvelle proteine de liaison aux ligands de glycoproteine p-selectine (psgl-1) et ses utilisations
WO1999051745A3 (fr) IMMUNISATION ADN CONTRE L'INFECTION A $i(CHLAMYDIA)
WO2003004613A3 (fr) Nouveaux isoformes de pgc-1 et applications de ceux-ci
EP2172214A3 (fr) Antigènes de Chlamydia et fragments d'ADN correspondants, et leurs utilisations
WO2001094390A3 (fr) 52906, 33408, et 12189, nouveaux elements de la famille de canaux de potassium et leurs utilisations
WO1999015669A3 (fr) Toxine de clostridium, et procede de preparation de compositions immunogenes
WO2002026984A3 (fr) Proteines d'interaction de canaux potassiques (pcip) et leurs procedes d'utilisation
WO2003068935A3 (fr) Méthodes thérapeutiques et diagnostiques
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
AU2002359572A1 (en) 15603, a human ion channel family member
Bunn Jr Immune therapy for lung cancer: are we getting closer?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97526442

Format of ref document f/p: F

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载